Akoya Biosciences Inc Cash Flow-to-Debt Ratio
Akoya Biosciences Inc cash flow-to-debt ratio. Akoya Biosciences Inc (AKYA) has a Cash Flow-to-Debt Ratio of -0.06x as of March 2025, meaning its operating cash flow of $-7.21 Million could theoretically repay 0% of its total liabilities ($118.54 Million) in one year. See AKYA FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Akoya Biosciences Inc (2019–2024)
Cash flow-to-debt ratio of Akoya Biosciences Inc from 2019 to 2024. Historical debt coverage capacity for Akoya Biosciences Inc across 6 annual periods. Also explore Akoya Biosciences Inc (AKYA) equity growth momentum to track the company's year-over-year net asset growth rate.
Akoya Biosciences Inc Cash Flow-to-Debt Ratio by Year (2019–2024)
Akoya Biosciences Inc cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for Akoya Biosciences Inc. For the full cash flow conversion analysis, see Akoya Biosciences Inc cash conversion from operations.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.38x | $-44.10 Million | $117.41 Million | ▲ +6.6% |
| 2023 | -0.40x | $-50.90 Million | $126.60 Million | ▲ +11.7% |
| 2022 | -0.46x | $-53.50 Million | $117.45 Million | ▲ +12.2% |
| 2021 | -0.52x | $-36.07 Million | $69.56 Million | ▼ -347.8% |
| 2020 | -0.12x | $-6.84 Million | $59.09 Million | ▼ -0.5% |
| 2019 | -0.12x | $-13.78 Million | $119.57 Million | — |